An observational study in Breast Neoplasms, sponsored by Manchester University NHS Foundation Trust. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-22.
Sponsored by Manchester University NHS Foundation Trust · Observational
Approximately 4,000 women undergo a mastectomy for breast cancer each year in the UK and around 1,500 will have an immediate breast reconstruction. Approximately half of these ladies will have an implant-based breast reconstruction, of which many have an "implant-assisted" breast reconstruction with an Acellular Dermal Matrix.
Strattice™ is an Acellular Dermal Matrix (a pig skin product) made by Acelity. It is used to cover and disguise the lower part of the breast implant. Acellular Dermal Matrices have only been widely used for the last eight years and long-term outcomes for women who have had this form of reconstruction are lacking. Despite this, it is one of the most commonly offered methods of breast reconstruction in the UK for both ladies with a diagnosis of breast cancer and in the risk-reduction setting.
The objective of this study is to assess long-term outcomes of Strattice™-based breast reconstructions in multiple Breast Surgery Centres across the UK. This will be a case-control study comparing women who have had an immediate implant-based breast reconstruction with Strattice™ (case) or without (control). This will be achieved by review and analysis of retrospective data from patients who have undergone immediate breast reconstruction using implants with or without Strattice™ following either a diagnosis breast cancer or for risk-reduction. In addition there will be a prospective clinical assessment of the reconstruction outcomes. Outcomes assessed will include complications, surgical re-interventions and aesthetic results. These will be related to co-morbid conditions and other risk factors. Data will also be collected on unplanned interventions associated with a cost, if available.
Primary Outcome The primary outcome measure will be unexpected loss of the implant.
Secondary Outcomes
To investigate short and long-term outcomes with Strattice™ including:
Study Design
Medical records, including clinic letters, nursing records and anaesthetic charts will be reviewed to collect data on:
Additional prospective data analysed will include:
Assessment of Contracture Using the Baker Breast Contracture Scale, the researcher will assess the Baker Grade for each breast to assess the level of capsular contracture.
Baker Grade Parameters I the breast is normally soft and looks natural II the breast is a little firm but looks normal III the breast is firm and looks abnormal IV the breast is hard, painful, and looks abnormal
Inclusion Criteria
Exclusion Criteria
Study Size and Statistical Analysis
Study Sites:
University Hospital of South Manchester Newcastle Upon Tyne Hospitals NHS Trust Bradford Teaching Hospitals NHS Foundation Trust
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 121 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Manchester University NHS Foundation Trust is the lead sponsor of 135 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Women having immediate breast reconstruction with partial or total Strattice cover
Procedure: Strattice
Women having immediate implant based breast reconstruction where no Strattice has been used
Implant based reconstruction with strattice cover of part or all of implant
Percentage of patients planned loss of implant within 12 months of immediate reconstruction
Time frame: 12 months
Quality of Life questionnaire
Time frame: 8 years
In-patient treatment costs
Time frame: 8 years
Ipsilateral Revision rates
Time frame: 1-8 years
Cosmesis
Cosmesis domains of Breast-Q quality of life questionnaire and likert 1-5 scale
Time frame: 1-8 years
Breast Reconstruction softness
Using tonometric measurement of breast softness
Time frame: 1-8 years
Regional pain
Using pain domain of Breast-Q Quality of Life questionnaire
Time frame: 1-8 years
loco-regional cancer recurrence
Time frame: 1-8 years
Morbidity
Time frame: 1-8 years
Effect of Radiotherapy
Patients will be recorded as to whether they have or have not received radiotherapy. Effect of radiotherapy on the primary and secondary outcome measures will be compared between and within groups
Time frame: 1-8 years
No study locations are listed for this record.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Manchester University NHS Foundation Trust